Gilead Sciences, Inc. Stock

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
67.31 USD -0.65% Intraday chart for Gilead Sciences, Inc. -3.76% -16.91%
Sales 2024 * 27.52B Sales 2025 * 27.97B Capitalization 84.48B
Net income 2024 * 6.54B Net income 2025 * 6.86B EV / Sales 2024 * 3.54 x
Net Debt 2024 * 12.8B Net Debt 2025 * 6.46B EV / Sales 2025 * 3.25 x
P/E ratio 2024 *
13.4 x
P/E ratio 2025 *
12.2 x
Employees 18,000
Yield 2024 *
4.63%
Yield 2025 *
4.83%
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.09%
1 week-2.41%
Current month-7.51%
1 month-8.06%
3 months-21.57%
6 months-12.75%
Current year-16.37%
More quotes
1 week
67.62
Extreme 67.62
69.76
1 month
67.62
Extreme 67.62
74.28
Current year
67.62
Extreme 67.62
87.87
1 year
67.62
Extreme 67.62
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 Jan. 31
More insiders
Date Price Change Volume
24-04-16 67.31 -0.65% 4,974,962
24-04-15 67.75 -0.47% 7,717,826
24-04-12 68.07 -0.84% 5,691,760
24-04-11 68.65 +0.78% 6,071,511
24-04-10 68.12 -2.60% 7,983,148

Delayed Quote Nasdaq, April 15, 2024 at 04:00 pm EDT

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.75 USD
Average target price
86.26 USD
Spread / Average Target
+27.32%
Consensus